新相微(688593.SH):MicroLED產品目前應用於AR眼鏡領域
格隆匯5月13日丨新相微(688593.SH)在投資者互動平臺表示,公司MicroLED產品憑藉其高集成度、低功耗和卓越的穩定性等核心技術優勢,目前應用於AR眼鏡領域,爲虛擬現實交互、遠程協作等場景提供顯示解決方案。未來,公司將持續深化技術創新和產業佈局,加速產品迭代,重點突破關鍵技術,拓展與客戶的戰略合作,進一步滿足AI領域需求,通過持續的技術迭代和生態共建,推動虛擬現實交互體驗的升級。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.